The European Commission has mounted a robust defence of its decision not to approve an orphan drug from a French company against the advice of the European Medicines Agency's scientific committee, the CHMP, and the standing committee of member state representatives1.
Addressing members of a European Parliament committee on 21 June, Patricia Brunko, head of the commission's pharmaceuticals unit, said that...




